Scalper1 News
Heron Therapeutics (HRTX) stock soared Wednesday after the biotech company reported success late Tuesday in a midstage trial of its drug for post-operative pain. Heron’s phase two study treated 64 patients who’d undergone a bunion removal. Those who took a 400 mg dose of Heron’s candidate HTX-011 showed a 69% reduction in pain intensity in the first 24 hours compared with the placebo group, and a 40% reduction after 72 hours. Patients on the drug Scalper1 News
Scalper1 News